Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Edoxaban Tosylate

FDA-approved product (tablet, oral), marketed as Savaysa.

Registered studies
22
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Edoxaban Tosylate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Atrial fibrillation
  • Deep vein thrombosis
  • Pulmonary embolism
  • Recurrent thrombophlebitis
  • Stroke
  • Venous thromboembolism

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Direct factor xa inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA62.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae38.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis59.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

22registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Edoxaban Tosylate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-4.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.1 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Edoxaban Tosylate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Canadian EdoxAban(Lixiana®) Registry in Patients With ATrial Fibrillation/Flutter With Confirmed ValvUlar HeaRt DiseasE

    NCT03488420 · start 2019-04-30

    Registered record
    Registry ID
    NCT03488420
    Conditions
    Atrial Fibrillation and Flutter; Valvular Heart Disease
    Interventions
    Edoxaban Pill
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-04-30
    Completion
    2025-04-03
    Enrolment
    136

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation and Flutter; Valvular Heart Disease
    InterventionEdoxaban Pill
    PhaseNot recorded
    Registry statusCompleted

  • Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

    NCT03395639 · start 2018-05-15

    Registered record
    Registry ID
    NCT03395639
    Conditions
    Cardiac Disease
    Interventions
    Edoxaban; Standard of Care (SOC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-05-15
    Completion
    2021-12-03
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiac Disease
    InterventionEdoxaban; Standard of Care (SOC)
    PhasePhase 3
    Registry statusCompleted

  • Study of DU-176b Aged 80 Years or Older

    NCT02801669 · start 2016-08-05

    Registered record
    Registry ID
    NCT02801669
    Conditions
    Atrial Fibrillation
    Interventions
    Du-176b; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08-05
    Completion
    2019-12-27
    Enrolment
    984

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionDu-176b; placebo
    PhasePhase 3
    Registry statusCompleted

  • Cancer Venous Thromboembolism (VTE)

    NCT02073682 · start 2015-07-16

    Registered record
    Registry ID
    NCT02073682
    Conditions
    Venous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer
    Interventions
    Edoxaban; Dalteparin; Low molecular weight heparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-07-16
    Completion
    2017-09-15
    Enrolment
    1,046

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism (VTE); Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Cancer
    InterventionEdoxaban; Dalteparin; Low molecular weight heparin
    PhasePhase 3
    Registry statusCompleted

  • Influence of Edoxaban on Coagulability and Thrombin Generation: An in Vitro Study Focusing on Thrombelastography

    NCT02448901 · start 2015-04

    Registered record
    Registry ID
    NCT02448901
    Conditions
    Heart Failure
    Interventions
    Edoxaban
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2016-03
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure
    InterventionEdoxaban
    PhaseNot recorded
    Registry statusUnknown

  • Edoxaban vs. Warfarin in Subjects Undergoing Cardioversion of Nonvalvular Atrial Fibrillation (NVAF)

    NCT02072434 · start 2014-03-25

    Registered record
    Registry ID
    NCT02072434
    Conditions
    Atrial Fibrillation
    Interventions
    Edoxaban; Warfarin; Enoxaparin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-03-25
    Completion
    2016-02-03
    Enrolment
    2,199

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionEdoxaban; Warfarin; Enoxaparin
    PhasePhase 3
    Registry statusCompleted

  • Edoxaban for TIA and Acute Minor Stroke

    NCT02221102 · start 2013-12

    Registered record
    Registry ID
    NCT02221102
    Conditions
    Ischemia; Stroke; Cerebral Infarction
    Interventions
    Aspirin; edoxaban; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2013-12
    Completion
    2016-06
    Enrolment
    3,700

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIschemia; Stroke; Cerebral Infarction
    InterventionAspirin; edoxaban; placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • A Randomized, Open-Label, Parallel-Group, Multi-Center Study for the Evaluation of Efficacy and Safety of Edoxaban Monotherapy Versus Low Molecular Weight (LMW) Heparin/Warfarin in Subjects With Symptomatic Deep-Vein Thrombosis

    NCT01662908 · start 2012-08

    Registered record
    Registry ID
    NCT01662908
    Conditions
    Deep Vein Thrombosis; Venous Thrombosis
    Interventions
    edoxaban tosylate; enoxaparin/unfractionated heparin; warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2014-03
    Enrolment
    85

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDeep Vein Thrombosis; Venous Thrombosis
    Interventionedoxaban tosylate; enoxaparin/unfractionated heparin; warfarin
    PhasePhase 2
    Registry statusCompleted

  • Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs

    NCT01857583 · start 2012-03

    Registered record
    Registry ID
    NCT01857583
    Conditions
    Venous Thromboembolism
    Interventions
    15mg DU-176b; 30mg DU-176b; Fondaparinux
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2012-12
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    Intervention15mg DU-176b; 30mg DU-176b; Fondaparinux
    PhasePhase 3
    Registry statusCompleted

  • Safety and Pharmacokinetics Study of DU-176b Administered to Non-valvular Atrial Fibrillation With Severe Renal Impairment

    NCT01857622 · start 2011-11

    Registered record
    Registry ID
    NCT01857622
    Conditions
    Non-valvular Atrial Fibrillation
    Interventions
    DU-176b 15mg; DU-176b 30mg; DU-176b 60mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-11
    Completion
    2013-01
    Enrolment
    93

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-valvular Atrial Fibrillation
    InterventionDU-176b 15mg; DU-176b 30mg; DU-176b 60mg
    PhasePhase 3
    Registry statusCompleted

  • Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).

    NCT00986154 · start 2009-10

    Registered record
    Registry ID
    NCT00986154
    Conditions
    Venous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism; Venous Thrombosis
    Interventions
    edoxaban tosylate(DU-176b); low molecular weight heparin/unfractionated heparin; warfarin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-10
    Completion
    2013-04
    Enrolment
    8,292

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism; Deep Vein Thrombosis (DVT); Pulmonary Embolism (PE); Thromboembolism +1 more
    Interventionedoxaban tosylate(DU-176b); low molecular weight heparin/unfractionated heparin; warfarin
    PhasePhase 3
    Registry statusCompleted

  • A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty

    NCT01181167 · start 2009-05

    Registered record
    Registry ID
    NCT01181167
    Conditions
    Prevention; Venous Thromboembolism
    Interventions
    edoxaban; enoxaparin sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-05
    Completion
    2010-03
    Enrolment
    610

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrevention; Venous Thromboembolism
    Interventionedoxaban; enoxaparin sodium
    PhasePhase 3
    Registry statusCompleted

  • A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty

    NCT01181102 · start 2009-03

    Registered record
    Registry ID
    NCT01181102
    Conditions
    Venous Thromboembolism
    Interventions
    edoxaban; enoxaparin sodium
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-03
    Completion
    2010-02
    Enrolment
    716

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    Interventionedoxaban; enoxaparin sodium
    PhasePhase 3
    Registry statusCompleted

  • Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation

    NCT00781391 · start 2008-11

    Registered record
    Registry ID
    NCT00781391
    Conditions
    Stroke; Atrial Fibrillation; Embolism
    Interventions
    warfarin tablets; Edoxaban tablets (high dose regimen-60mg); Edoxaban tablets (low dose regimen-30mg); placebo warfarin; placebo edoxaban
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-11
    Completion
    2013-05
    Enrolment
    21,105

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStroke; Atrial Fibrillation; Embolism
    Interventionwarfarin tablets; Edoxaban tablets (high dose regimen-60mg); Edoxaban tablets (low dose regimen-30mg); placebo warfarin +1 more
    PhasePhase 3
    Registry statusCompleted

  • Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery

    NCT01181141 · start 2008-10

    Registered record
    Registry ID
    NCT01181141
    Conditions
    Venous Thromboembolism
    Interventions
    DU-176b (edoxaban); Enoxaparin sodium 20mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2008-10
    Completion
    2010-02
    Enrolment
    92

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVenous Thromboembolism
    InterventionDU-176b (edoxaban); Enoxaparin sodium 20mg
    PhasePhase 3
    Registry statusCompleted